Black Diamond Therapeutics (BDTX) Assets (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Assets came in at $132.9 million in Q1 2026, down 24.58% YoY from $176.2 million in Q1 2025, and down 7.05% on a QoQ basis from $143.0 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Assets (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Assets data on file, last reported at $132.9 million in Q1 2026.
- Quarterly Assets fell 24.58% year-over-year to $132.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.9 million (down 24.58% YoY) and the FY2025 annual result came in at $143.0 million, up 16.61% from the prior year.
- Assets eased to $132.9 million in Q1 2026, from $143.0 million in the prior quarter.
- In the past five years, Assets ranged from a high of $219.5 million in Q1 2022 to a low of $119.9 million in Q2 2023.
- A 5-year average of $157.1 million and a median of $156.3 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets slumped 39.71% — and 2024, when it advanced 25.11%.
- Tracing BDTX's Assets over 5 years: stood at $156.3 million in 2022, then grew by 1.48% to $158.6 million in 2023, then dropped by 22.66% to $122.6 million in 2024, then increased by 16.61% to $143.0 million in 2025, then decreased by 7.05% to $132.9 million in 2026.
- The last three Assets figures came in at $132.9 million (Q1 2026), $143.0 million (Q4 2025), and $157.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 125.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.03 Mn |
| Mar 31, 2026 | 132.92 Mn |
| Dec 31, 2025 | 143.01 Mn |
| Sep 30, 2025 | 157.73 Mn |
| Jun 30, 2025 | 166.39 Mn |
| Mar 31, 2025 | 176.25 Mn |
| Dec 31, 2024 | 122.64 Mn |
| Sep 30, 2024 | 137.90 Mn |
| Jun 30, 2024 | 149.99 Mn |
| Mar 31, 2024 | 142.52 Mn |
| Dec 31, 2023 | 158.57 Mn |
| Sep 30, 2023 | 172.38 Mn |
| Jun 30, 2023 | 119.88 Mn |
| Mar 31, 2023 | 135.58 Mn |
| Dec 31, 2022 | 156.26 Mn |
| Sep 30, 2022 | 180.42 Mn |
| Jun 30, 2022 | 198.83 Mn |
| Mar 31, 2022 | 219.48 Mn |
| Dec 31, 2021 | 247.68 Mn |
| Sep 30, 2021 | 274.13 Mn |